Allegis Investment Advisors LLC lifted its position in Steris PLC (NYSE:STE) by 73.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,297 shares of the medical equipment provider’s stock after purchasing an additional 3,102 shares during the quarter. Allegis Investment Advisors LLC’s holdings in Steris were worth $638,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Boston Financial Mangement LLC boosted its position in shares of Steris by 3.5% during the 4th quarter. Boston Financial Mangement LLC now owns 119,950 shares of the medical equipment provider’s stock worth $10,492,000 after purchasing an additional 4,105 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Steris by 6.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 9,810 shares of the medical equipment provider’s stock valued at $858,000 after purchasing an additional 630 shares during the last quarter. American Century Companies Inc. raised its stake in Steris by 14.6% in the 4th quarter. American Century Companies Inc. now owns 1,194,167 shares of the medical equipment provider’s stock valued at $104,454,000 after purchasing an additional 152,346 shares during the last quarter. Meeder Asset Management Inc. increased its stake in shares of Steris by 1,122.4% during the 4th quarter. Meeder Asset Management Inc. now owns 1,198 shares of the medical equipment provider’s stock valued at $104,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado increased its stake in shares of Steris by 4.3% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 847,843 shares of the medical equipment provider’s stock valued at $74,161,000 after acquiring an additional 34,823 shares during the last quarter. 89.47% of the stock is owned by institutional investors and hedge funds.
In related news, VP Karen L. Burton sold 1,500 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.59, for a total value of $128,385.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Sudhir K. Pahwa sold 2,000 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $92.09, for a total value of $184,180.00. The disclosure for this sale can be found here. Company insiders own 2.55% of the company’s stock.
Steris (NYSE:STE) last announced its earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.05. Steris had a return on equity of 11.57% and a net margin of 9.42%. The business had revenue of $661.90 million during the quarter, compared to analysts’ expectations of $663.17 million. During the same quarter last year, the business posted $0.98 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. equities analysts expect that Steris PLC will post 4.13 EPS for the current fiscal year.
A number of analysts have recently issued reports on STE shares. KeyCorp reiterated an “overweight” rating and set a $101.00 target price (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research lowered Steris from a “buy” rating to a “sell” rating in a research report on Monday, November 6th. TD Securities upped their target price on Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a research report on Thursday, November 9th. Northcoast Research set a $102.00 price target on Steris and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, Raymond James Financial reissued a “market perform” rating and set a $100.00 price target on shares of Steris in a research report on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $84.80.
WARNING: “Allegis Investment Advisors LLC Has $638,000 Stake in Steris PLC (STE)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://weekherald.com/2018/02/15/allegis-investment-advisors-llc-has-638000-stake-in-steris-plc-ste.html.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.